Metastatic Breast Cancer: Palbociclib Now Approved for Men

​ The FDA has now expanded the indication for palbociclib (Ibrance®, Pfizer Inc.) in combination with an aromatase inhibitor or fulvestrant (Faslodex®, AstraZeneca) to include men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. Because breast cancer in men is rare, comprising less than 1% of all breast cancer cases, men with breast cancer are more likely to be diagnosed at an older age and with a more advanced st...
Continue reading

The Impact of the FDA’s Revised Mammography Guidelines: Theresa W. Gillespie, PhD, MA, RN

For the first time in over 20 years, the FDA has proposed amendments to the Mammography Quality Standards Act (MQSA) in an effort to expand the information provided to patients and physicians, modernize standards for mammograms, and enable better enforcement of safety and quality regulations. In this interview with i3 Health, Theresa W. Gillespie, PhD, MA, RN, Professor at Emory University School of Medicine and at Emory's Winship Cancer Institute, discusses the significance of these changes and...
Continue reading

How Does Green Tea Lower Breast Cancer Risk?

Catechins—phenolic compounds with antioxidant properties—from green tea extract (GTE) lower the risk of breast cancer, but how do these compounds do so? In an effort to find out, a team of researchers investigated one potential theory: that GTE may modulate hormones. The clinical trial compared levels of sex hormones and insulin-like growth factors (IGF) in 1,012 healthy postmenopausal women randomly assigned to take a GTE capsule (n=538) or a placebo pill (n=474). Women in the GTE group took fo...
Continue reading

Eribulin Is Effective in Metastatic Breast Cancer

For many patients with metastatic breast cancer, a resistance to hormone therapy develops, and cumulative toxicity, comorbidities, performance status, and prior adjuvant therapy influence the next step for treatment. Due to all of these factors, finding an effective, well-tolerated treatment can be difficult. However, results from a phase 3 clinical trial, published in the European Journal of Cancer, reveal that scientists are a step closer to this goal: eribulin (Halaven®, Eisai Inc.) monothera...
Continue reading

An Alternative to Biopsy: Improved CTC Collection Method

​ Researchers at the University of Michigan have developed a prototype of a wearable device that can continuously collect circulating tumor cells (CTCs) directly from a patient's bloodstream. The investigators hope that this device, which has thus far proven successful in canine models, could ultimately be used as an alternative to biopsies. Circulating tumor cells, which circulate through lymphatic channels and blood after they are shed from the primary tumor, are the basis for cancer metastase...
Continue reading

© Copyright 2019 i3 Health. All rights reserved.